Evidence map›Paper›PMID 40398537›Full record

ReviewPharmacology & therapeutics2025

Human intestinal enteroids: Nonclinical applications for predicting oral drug disposition, toxicity, and efficacy.

Eimear T O'Mahony, Christopher M Arian, Kayenat S Aryeh, Kai Wang, Kenneth E Thummel, Edward J Kelly

Abstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Advances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eimear T O'MahonyDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States of America.
Christopher M ArianDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States of America.
Kayenat S AryehDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States of America.
Kai WangDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States of America.
Kenneth E ThummelDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States of America; Center of Excellence for Natural Product Drug Interaction Research, Spokane, WA, United States of America.
Edward J KellyDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States of America; Kidney Research Institute, University of Washington, Seattle, WA, United States of America. Electronic address: edkelly@uw.edu.

Funding

XENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Nicole Ann Errett · 1995 to 2026
$42.5M
Pharmacology CoreU54AT008909 · NCCIH · WASHINGTON STATE UNIVERSITY · PI PAINE, MARY F · 2015 to 2024
$22.4M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
Pharmacological Sciences SupplementT32GM007750 · NIGMS · UNIVERSITY OF WASHINGTON · PI ATKINS, WILLIAM M · 1985 to 2023
$12.6M
NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
Identification, Quantification, and Functional Characterization of Transporters in the Human Placenta and Developing GutUC2HD113041 · NICHD · UNIVERSITY OF WASHINGTON · PI JASHVANT D Unadkat, Joanne Wang · 2023 to 2026
$3.7M
NCATS NIH HHS TL1 TR002318NCCIH NIH HHS U54 AT008909NICHD NIH HHS UC2 HD113041NIDDK NIH HHS P30 DK089507NIEHS NIH HHS P30 ES007033NIGMS NIH HHS T32 GM007750
6 · The paper itself

Abstract

The application of human enteroid systems presents a significant opportunity within the drug development pipeline, highlighting considerable potential for advancements in the characterization and evaluation of new molecular entities. Derived from LGR5

Indexed as

Intestinal MucosaOrganoidsAdministration, OralAnimalsDrug DevelopmentDrug Evaluation, PreclinicalDrug InteractionsHumansPharmaceutical PreparationsPharmaceutical PreparationsBioavailabilityDrug dispositionDrug efficacyDrug toxicityEnteroidsIn vitroOrganoidsSmall intestine

Identifiers

PMID40398537
PMCPMC12354307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.